AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26261386
Drug: itraconazole continual
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: itraconazole continual therapy
Trial: 26261386
Drug: itraconazole pulse
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: itraconazole pulse therapy
Trial: 26261386
Drug: terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terbinafine 250 mg/d
Trial: 19555446
Drug: Prebiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic mixture (0.8 g/dL of scGOS and lcFOS, ratio 9:1)
Trial: 31077311
Drug: Cisplatin/gemcitabine chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/gemcitabine chemotherapy
Trial: 23183442
Drug: Intramuscular quinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular quinine (loading dose of 20 mg quinine dihydrochloride/kg)
Trial: 16448867
Drug: Methyldopa preparation
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa preparation 1
Trial: 16448867
Drug: Methyldopa preparation
RxNorm normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methyldopa preparation 2
Trial: 8929256
Drug: pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 40 mg o.d.
Trial: 8929256
Drug: gemfibrozil +
RxNorm normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gemfibrozil + pravastatin (same doses)
Trial: 1404679
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin or low-dose aspirin (80 to 325 mg daily)
Trial: 1404679
Drug: Overall aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Overall aspirin usage
Trial: 3981950
Drug: Low molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular-weight heparin (LMW heparin) at 50% of the normal unfractionated heparin (UF heparin) dose
Trial: 3981950
Drug: Low molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular-weight heparin (LMW heparin)
Trial: 3981950
Drug: UF heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UF heparin and LMW heparin
Trial: 3286383
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 11.1 mg/kg per day (group A)
Trial: 3286383
Drug: Ursomenth (UDCA/menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursomenth (UDCA/menthol mixture: 4.75 mg/kg per day each) (group B)
Trial: 30916194
Drug: β1 specific
RxNorm normalized name: PACIFIC OYSTER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β1 specific beta-blockers + alpha 1-blocker
Trial: 30916194
Drug: β1 non-specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β1 non-specific beta-blockers
Trial: 23499394
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (lukewarm water foot bath)
Trial: 21545249
Drug: Inhaled montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled montelukast 1 mg plus inhaled mometasone 220 μg
Trial: 21545249
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus inhaled mometasone 220 μg
Trial: 19789401
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of bone marrow-derived mononuclear cells (BMC) within 7 days after successful reperfusion therapy for AMI.
Trial: 16730616
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg/d for 12 weeks
Trial: 16730616
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg/d for 12 weeks with aggressive toenail debridement
Trial: 2826526
Drug: Insulin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.1 U/kg, iv) followed by placebo
Trial: 2826526
Drug: Insulin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (0.1 U/kg, iv) followed by oral clonidine (0.150 mg)
Trial: 2826526
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (0.150 mg) followed by iv placebo
Trial: 2826526
Drug: Oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral clonidine (0.150 mg) followed by iv insulin (0.1 U/kg)
Trial: 22111770
Drug: Daily supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplementation with multiple micronutrient powder (MMP) for 24 weeks (n = 111)
Trial: 22111770
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly supplementation with multiple micronutrient powder (MMP) for 24 weeks (n = 115)
Trial: 19271165
Drug: Xinyue Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinyue Capsule (XYC) plus Composite Salvia Tablet (CST)
Trial: 16971855
Drug: 4% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% human albumin with >3 L of fluids in the first 24 hrs
Trial: 15563344
Drug: Caffeine (1.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (1.75 mg/kg) three times daily for 4 consecutive weeks
Trial: 9394856
Drug: Anastrozole, 1
RxNorm normalized name: Anastrozole, 1 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole, 1 mg once daily, orally
Trial: 9394856
Drug: Formestane, 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formestane, 250 mg every 2 weeks, intramuscularly
Trial: 28931197
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone 0.4 mg/kg/day for 4 weeks, tapered to 0.2 mg/kg/day for 2 months, and to 0.1 mg/kg/day for the last 2 months (Group A)
Trial: 28931197
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone tapered within 2 months (Group B)
Trial: 25348255
Drug: LY500307 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY500307 1 mg
Trial: 25348255
Drug: LY500307 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY500307 3 mg
Trial: 25348255
Drug: LY500307 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY500307 10 mg
Trial: 25348255
Drug: LY500307 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY500307 25 mg
Trial: 23989256
Drug: Minodronate (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minodronate (1.0 mg daily)
Trial: 23989256
Drug: Risedronate (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (daily treatment combined with 1000 IU ergocalciferol and 1200 mg elemental calcium)
Trial: 21341397
Drug: S-equol (10-320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-equol (10-320 mg single dose)
Trial: 21341397
Drug: S-equol (10-160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-equol (10-160 mg, BID for 14 days)
Trial: 21341397
Drug: S-equol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-equol (20 mg single dose with food)
Trial: 21341397
Drug: S-equol (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-equol (various doses)
Trial: 21341397
Drug: S-equol (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-equol (320 mg single dose)
Trial: 15310633
Drug: Tandospirone 10
RxNorm normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandospirone 10 mg
Trial: 8995995
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (5 mg) - single dose
Trial: 8995995
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol (5 mg) - double dose
Trial: 8355469
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (15 g/day)
Trial: 3117876
Drug: Clomipramine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (150 mg)
Trial: 29906273
Drug: 25-hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxyvitamin D concentrations ≥60 ng/ml
Trial: 29906273
Drug: 25-hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxyvitamin D concentrations <20 ng/ml
Trial: 19664300
Drug: High-wheat fibre
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-wheat fibre cereal (24 g fibre/d)
Trial: 11563413
Drug: Rizatriptan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan (1 mg) with Paroxetine (20 mg once daily)
Trial: 11563413
Drug: Rizatriptan (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rizatriptan (1 mg)
Trial: 7554037
Drug: CPT-11 AUC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 AUC (ng h ml-1) using a trivariate model: CPT‐11 AUC = 0.820 x C0.5h + 0.402 x C1h + 15.47 x C6h + 928
Trial: 7554037
Drug: SN-38 AUC
RxNorm normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SN-38 AUC (ng h ml-1) using a trivariate model: SN‐38 AUC = 4.05 x C0.5h ‐0.81 x C1h + 23.01 x C6h ‐ 69.78
Trial: 30393935
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (ATRA, cytarabine, anthracyclines)
Trial: 29450452
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy plus regional hyperthermia
Trial: 22825691
Drug: Paclitaxel (175
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (175 mg/m2 intravenously over 3 h) plus Carboplatin (AUC 5 intravenously over 30 min)
Trial: 20178395
Drug: Personalized letter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized letter from a practicing pharmacist containing treatment recommendations for patients with upcoming primary care visits (intervention group, n = 150)
Trial: 17141481
Drug: Anti-Helicobacter pylori
RxNorm normalized name: Anti-Helicobacter pylori IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Helicobacter pylori treatment (clarithromycin, amoxicillin, lansoprazole)
Trial: 17141481
Drug: Probiotic combination
RxNorm normalized name: PROBIOTIC COMBINATION CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic combination (Lactobacillus rhamnosus GG, L. rhamnosus LC705, Propionibacterium freudenreichii ssp. shermanii JS, Bifidobacterium breve Bb99)
Trial: 15657401
Drug: Maintenance rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance rituximab therapy (standard 4-week courses administered at 6-month intervals)
Trial: 15657401
Drug: Rituximab re-treatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab re-treatment at progression
Trial: 7794307
Drug: Nystatin 50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nystatin 50,000 U/kg four times daily
Trial: 7794307
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B 25 mg/kg four times daily
Trial: 3277911
Drug: OKY‐046 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKY‐046 (400 mg)
Trial: 3277911
Drug: OKY‐046 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKY‐046 (600 mg/day for 3 days)
Trial: 3277911
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg) + OKY‐046
Trial: 30203101
Drug: Standard triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triamcinolone acetonide crystalline suspension (TAcs) 40 mg
Trial: 18061001
Drug: New antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New antiarrhythmic drugs
Trial: 10783213
Drug: Hospital discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital discharge while taking a beta-blocker
Trial: 10783213
Drug: Hospital discharge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital discharge while taking an angiotensin-converting enzyme inhibitor
Trial: 3886402
Drug: Cadralazine 15
RxNorm normalized name: cadralazine
DrugBank: Cadralazine (DB13452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadralazine 15 mg/day
Trial: 30326380
Drug: Methadone 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone 0.1 mg kg-1
Trial: 30326380
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg kg-1
Trial: 18940484
Drug: E‐L pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E‐L pretreatment (epinephrine and lidocaine mixture)
Trial: 16088363
Drug: High-dose simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose simvastatin (80 mg/daily)
Trial: 16088363
Drug: Pravastatin 40
RxNorm normalized name: pravastatin 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 40 mg/daily
Trial: 16088363
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/daily
Trial: 12017384
Drug: Isoflurane administration
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane administration via microporous capillary membrane oxygenator
Trial: 12017384
Drug: Isoflurane administration
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoflurane administration via diffusion membrane oxygenator
Trial: 10080835
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose BCG
Trial: 10080835
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose BCG
Trial: 10080835
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose BCG with IFN-alpha
Trial: 10080835
Drug: All treatment
RxNorm normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All treatment arms (High dose BCG, Low dose BCG, Low dose BCG with IFN-alpha)
Trial: 10080835
Drug: Intravesical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical treatment
Trial: 7590403
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (50 mg zinc as 220 mg zinc sulphate daily for 4 weeks)
Trial: 31761416
Drug: Ultrasound-guided bilateral
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided bilateral superficial cervical plexus block with 10 ml of ropivacaine 0.5%
Trial: 23572466
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low dose naltrexone (VLNTX) added to methadone taper
Trial: 23572466
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of VLNTX and clonidine
Trial: 23572466
Drug: In-treatment smokers
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-treatment smokers (n = 96)
Trial: 19597420
Drug: Early administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early administration of rhG‐CSF (4th day)
Trial: 19597420
Drug: Late administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Late administration of rhG‐CSF (7th day)
Trial: 17368530
Drug: Homeopathic care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic care (HC: individual homeopathic consultations with any homeopathic medicine in any potency being prescribed)
Trial: 17368530
Drug: Self-prescribed homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-prescribed homeopathic medicine (SPH) in C-30 administered twice weekly for 12 weeks
Trial: 17368530
Drug: Self-prescribed homeopathic
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-prescribed homeopathic medicine (SPH)
Trial: 15353916
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) administered subcutaneously in a fixed daily dose
Trial: 15353916
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral anticoagulant therapy (OAT)
Trial: 8490638
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral group psychotherapy with treatment intensity (high and low)
Trial: 24888929
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding (liquid diets commenced 2 hours after surgery)
Trial: 24888929
Drug: Delayed oral
RxNorm normalized name: lipase 12,000 UNT / amylase 39,000 UNT / protease 39,000 UNT Delayed Oral Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed oral feeding (liquid diets commenced 8 hours after surgery)
Trial: 1774568
Drug: Low-dose warfarin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose warfarin (LDW)
Trial: 6124654
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 20 mg clorazepate dipotassium (CZP)
Trial: 6124654
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 20 mg clorazepate dipotassium (CZP)
Trial: 6124654
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of 20 mg clorazepate dipotassium (CZP)
Trial: 24680796
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg daily for 8 weeks
Trial: 9924274
Drug: Moderately-fatty breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately-fatty breakfast (25.7 g fat; M)
Trial: 9924274
Drug: Low-fat high-carbohydrate
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat high-carbohydrate breakfast (5.5 g fat; L)
Trial: 8036679
Drug: Mefloquine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (15 mg/kg) plus artesunate (10 mg/kg)
Trial: 8036679
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose mefloquine (25 mg/kg)
Trial: 29676968
Drug: Low-dose milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose milk (120 mg/100 mL calcium, vitamin D3 30 UI/100 mL)
Trial: 29676968
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: milk (180 mg/100 mL calcium, 120 UI/100 mL vitamin D)
Trial: 29676968
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: milk (180 mg/100 mL calcium, 120 UI/100 mL vitamin D) and FOS (5 g/L)
Trial: 27380030
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of TAU
Trial: 23312049
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (rosuvastatin + fenofibric acid)
Trial: 18756744
Drug: Traditional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional therapy only
Trial: 14506629
Drug: Troglitazone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (200 mg/d)
Trial: 8767437
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg twice a day) for group 3
Trial: 8767437
Drug: Cisapride (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (30 mg) for group 2
Trial: 8767437
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug therapy for group 1
Trial: 30266309
Drug: Androgen Deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen Deprivation Therapy (ADT) with External Beam Radiation Therapy (EBRT)
Trial: 30266309
Drug: Androgen Deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen Deprivation Therapy (ADT) alone
Trial: 29742190
Drug: Cream-to-powder product
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cream-to-powder product
Trial: 20678687
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination (FDC) tablet of glimepiride/metformin 2/500 mg